scholarly journals Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal Surgery

1999 ◽  
Vol 159 (11) ◽  
pp. 1221 ◽  
Author(s):  
Edward Etchells ◽  
Robin S. McLeod ◽  
William Geerts ◽  
Paul Barton ◽  
Allan S. Detsky
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Colorectal Surgery ◽  
Economic Analysis ◽  
Low Molecular Weight Heparin ◽  
Low Dose ◽  
Low Molecular Weight ◽  
Dose Heparin ◽  
Low Dose Heparin

A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma

1996 ◽  
Vol 335 (10) ◽  
pp. 701-707 ◽  
Author(s):  
William H. Geerts ◽  
Richard M. Jay ◽  
Karen I. Code ◽  
Erluo Chen ◽  
John Paul Szalai ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Major Trauma ◽  
Low Dose ◽  
Low Molecular Weight ◽  
Dose Heparin ◽  
Low Dose Heparin

scholarly journals Venous Thromboembolism Following Colorectal Surgery for Suspected or Confirmed Malignancy

Thrombosis ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Brenton Sanderson ◽  
Kerry Hitos ◽  
John P. Fletcher
Keyword(s):  
Colorectal Cancer ◽  
Molecular Weight ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Mortality Rate ◽  
Colorectal Surgery ◽  
Low Molecular Weight Heparin ◽  
Low Dose ◽  
Low Molecular Weight ◽  
Pharmacological Prophylaxis

Surgery for colorectal cancer conveys a high risk of venous thromboembolism (VTE). The effect of thromboprophylactic regimens of varying duration on the incidence of VTE was assessed in 417 patients undergoing surgery between 2005 and 2009 for colorectal cancer. Low-dose unfractionated heparin (LDUH) was used in 52.7% of patients, low-molecular-weight heparin (LMWH) in 35.3%, and 10.7% received LDUH followed by LMWH. Pharmacological prophylaxis was continued after hospitalisation in 31.6%. Major bleeding occurred in 4% of patients. The 30-day mortality rate was 1.9%. The incidence of symptomatic VTE from hospital admission for surgery to 12 months after was 2.4%. There were no in-hospital VTE events. The majority of events occurred in the three-month period after discharge, but there were VTE events up to 12 months, especially in patients with more advanced cancer and multiple comorbidities.

Sign in / Sign up

Export Citation Format

Share Document